NEW YORK – Myriad Genetics and Personalis jointly announced on Friday a partnership in which Myriad will market Personalis' ImmunoID NeXT platform to certain pharmaceutical partners.
Under the non-exclusive collaboration, the financial details of which were not provided, Myriad will market the ImmunoID NeXT immunogenomics biomarker discovery platform to those of its pharmaceutical partners who use Myriad's MyRisk Hereditary Cancer Test, BRACAnalysis CDx, and/or MyChoice CDx assays.
The ImmunoID NeXT platform provides both exome and transcriptome assays for formalin-fixed paraffin-embedded cancer patient samples.
Personalis has also lent its platform to several other collaborations. It recently partnered with Ono Pharmaceutical and Japan's National Cancer Center to assess minimal residual disease in resectable rectal cancer using its ImmunoID NeXT assay and NeXT Personal MRD platforms.
Another collaboration last year provided Duke University and Olink Proteomics access to ImmunoID NeXT to study genomic, transcriptomic, and proteomic responses of gastroesophageal tumors following treatment with Keytruda.
Paul Diaz, president and CEO of Myriad, said in a statement that pharmaceutical customers are increasingly requesting complementary whole-exome and whole-transcriptome testing of patient tumors.
"Our goal is to provide full menu access to our customers and we are pleased to leverage Personalis' high-quality assays to expand our offering," he said.
"A key pillar of our strategy is to expand our reach through commercial partnerships and this new collaboration with Myriad is an exciting milestone of our progress," said Chris Hall, CEO and president of Personalis.